Novo Nordisk and Evotec selected three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases.

Harvard University joins Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center as the initial four academic institutions to participate in LAB eN².

A team of Harvard and Sloan Kettering scientists has developed compounds that can target and degrade proteins associated with acute myeloid leukemia (AML) and nearly doubled the life expectancy of mice with cancer in laboratory tests.

Mouse study suggests some aspects of autism are linked to the peripheral nerves found throughout the limbs and elsewhere